
    
      This study includes 2 single ascending dose (SAD) parts; (Part A) IV SAD (up to 5 planned
      dose level cohorts) and Part B SC SAD (up to 3 planned dose level cohorts).

      Safety assessments will include adverse events (AEs), concomitant medications, clinical
      laboratory, vital signs, 12-lead electrocardiogram, and physical examination. Serial blood
      samples for PK, PD, and anti-drug antibodies will be performed during each part of the study
      during the Treatment and Safety Evaluation Period.
    
  